Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

Abstract

This is a PDF file of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting. Nature is providing this early version of the typeset paper as a service to our authors and readers. The text and figures will undergo copyediting and a proof review before the paper is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers apply.

Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines

“…3a ). The N501Y substitution present in the B.1.1.7 and B.1.351 lineages, the mink-associated Y453F substitution, and the prevalent N439K mutation did not affect the neutralization potency of any RBD-NP- or HexaPro-elicited sera significantly, while these substitutions have been associated with loss of neutralization for some mAbs 44,46,65,66 . The E484K mutation reduced serum neutralizing activity by ∼5-fold and ∼7-fold for RBD-NP and HexaPro (GMT 1×10 2 ) compared to wild-type (D614G) SARS-CoV-2 S, respectively, whereas the E484A and E484D mutations did not significantly affect the neutralizing activity induced by either immunogen.…”

“…The recent emergence of several variants with numerous S mutations is especially concerning, specifically the B.1.1.7, B1.351, and P.1 lineages that originated in the UK, South Africa, and Brazil, respectively 40–42 . Some of these mutations lead to significant reductions in the neutralization potency of NTD- and RBD-specific mAbs, convalescent sera and Pfizer/BioNTech BNT162b2- or Moderna mRNA-1273-elicited sera 43–46 .…”

SARS-CoV-2 Portrayed Against HIV: Contrary Viral Strategies in Similar Disguise

“…As shown for P.1 variants in Brazil, VOCs may also facilitate coinfections with different SARS-CoV-2 lineages [335]. While animal experiments suggest that adenovirus vaccines still provide sufficient protection of disease after challenge with UK or SA variants [314], a clinical trial in South Africa showed that vaccine efficacy of an approved adenovirus vaccine dropped from >70% to ~10% in preventing mild or moderate disease [336]. Preliminary data indicate that natural infection with the SA variant induces a cross-neutralizing Ab response including potent neutralization of SA mutant viruses, indicating that targeted booster vaccines might be broadly effective [337,338].…”

“…Epidemiological studies suggest that the UK variant correlates with higher viral loads in patients [306], a >40% increased epidemiological growth [307,308], a longer duration of acute infection [309], and increased severity/death rate, particularly in patients of higher age and with comorbidities [310][311][312][313]. The UK variant acquired an enhanced affinity to ACE2 [314] while maintaining sensitivity to nAb responses though with 2-9 times reduced nAb titers in vaccinees and convalescent individuals [314][315][316]. Spike mutations present in the UK variant frequently confer resistance to NTD-directed nAbs, whereas neutralization by RBD-specific nAbs remains largely unaffected [317].…”

Molecular beacons allow specific RT-LAMP detection of B.1.1.7 variant SARS-CoV-2

“…Over the course of the pandemic, several genetic variants of concern have appeared and rapidly increased in frequency. The effects of these mutations remain unclear but there is concern that these variants may alter virus phenotype, affect detection and escape immune responses [1][2][3][4][5][6][7][8][9][10] .…”